Preparation of MUC-1 Oligomers Using an Improved Convergent Solid-phase Peptide Synthesis*

The sequentially repeating nature of the core mucin polypeptide chain MUC-1 on the surface of malignant cells makes it an excellent target for cancer immunotherapy. We describe a reliable and efficient method of synthesizing oligomers, up to five tandem repeats and oligomer heterotope derivatives with a 15-amino acid epitope from tetanus toxin using an improved convergent solid-phase peptide synthesis. The different oligomers were easily distinguishable by reverse-phase high pressure liquid chromatography, but they were poorly fixed and migrated with the same migration rate, irrespective of size, in electrophoretic studies. In contrast, the oligomer heterotopes exhibited size-dependent electrophoretic behavior but in high pressure liquid chromatography chromatograms the different heterotopes were eluted simultaneously in two peaks representing thel- and d-enantiomers of the derivatives. The oligomer heterotopes were recognized as antigens in Western blotting with a murine monoclonal antibody against the epitope APDTR. In enzyme immunoassay studies with the same antibody an increasing reactivity was observed against the larger oligomers and confirmed by inhibition assays as the MUC-1 pentamer was the most efficient inhibitor. These results support the suggestion that the pentamer attains a structure closer to the native conformation and is more immunogenic. In conclusion, large composite peptides can be reliably synthesized with the convergent solid-phase peptide strategy offering an attractive option to vaccine designing and development.

[1]  J. Taylor‐Papadimitriou,et al.  The Polymorphic Epithelial Mucin as a Target for Immunotherapy a , 1993, Annals of the New York Academy of Sciences.

[2]  E. Krambovitis,et al.  A simple enzyme immunoassay for detecting brucellosis antibodies. , 1992, FEMS microbiology immunology.

[3]  K. Barlos,et al.  Darstellung geschützter peptid-fragmente unter einsatz substituierter triphenylmethyl-harze , 1989 .

[4]  E. Gotschlich,et al.  A rapid, sensitive method for detection of alkaline phosphatase-conjugated anti-antibody on Western blots. , 1984, Analytical biochemistry.

[5]  I. Mckenzie,et al.  Epitope mapping of anti-breast and anti-ovarian mucin monoclonal antibodies. , 1992, Molecular immunology.

[6]  J. Rothbard,et al.  A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. , 1988, The Journal of biological chemistry.

[7]  J. Taylor‐Papadimitriou,et al.  A short sequence, within the amino acid tandem repeat of a cancer‐associated mucin, contains immunodominant epitopes , 1989, International journal of cancer.

[8]  Dimitrios Gatos,et al.  Synthesis of Prothymosin α (ProTα)—a Protein Consisting of 109 Amino Acid Residues , 1991 .

[9]  E. Giralt,et al.  Convergent solid-phase peptide synthesis , 1986 .

[10]  B. Hudson,et al.  Estimation of the size of collagenous polypeptides by sodium dodecyl sulfate--polyacrylamide gel electrophoresis. , 1981, Analytical biochemistry.

[11]  K. Barlos,et al.  Veresterung von partiell geschützten peptid-fragmenten mit harzen. Einsatz von 2-chlortritylchlorid zur synthese von Leu15 -gastrin I , 1989 .

[12]  W. Schäfer,et al.  Application of 2-chlorotrityl resin in solid phase synthesis of (Leu15)-gastrin I and unsulfated cholecystokinin octapeptide. Selective O-deprotection of tyrosine. , 2009, International journal of peptide and protein research.

[13]  J. Carrascosa,et al.  A precursor of the neck appendage protein of B. subtilis phage Φ 29 , 1974, FEBS letters.

[14]  I. Mckenzie,et al.  Mucins: Structure, function, and associations with malignancy , 1992, BioEssays : news and reviews in molecular, cellular and developmental biology.

[15]  R. Henderson,et al.  MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines , 1995, Immunological reviews.

[16]  J. Bártková,et al.  A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM‐3 is selectively exposed in a range of primary carcinomas , 1989, International journal of cancer.

[17]  J. Taylor‐Papadimitriou Report on the first international workshop on carcinoma‐associated mucins , 1991, International journal of cancer.

[18]  R. Metzgar,et al.  Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. , 1994, Cancer research.

[19]  N. Tjandra,et al.  Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core. , 1993, Cancer research.

[20]  J. Prachař,et al.  An improved colloidal silver staining method of protein blots on nitrocellulose membranes. , 1987, Folia biologica.

[21]  R. Lathe,et al.  A transcribed gene, containing a variable number of tandem repeats, codes for a human epithelial tumor antigen. cDNA cloning, expression of the transfected gene and over-expression in breast cancer tissue. , 1990, European journal of biochemistry.

[22]  R. W. Baldwin,et al.  Immunological and structural features of the protein core of human polymorphic epithelial mucin. , 1990, Molecular immunology.

[23]  A. Stefanakis,et al.  Comparison of different antibody-conjugate derivatives for the development of a sensitive and specific progesterone assay. , 1993, Journal of reproduction and fertility.

[24]  M. Lotze,et al.  A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. , 1996, The Journal of surgical research.

[25]  V. Apostolopoulos,et al.  Phase-I study of synthetic muc1 peptides in breast-cancer. , 1995, International journal of oncology.

[26]  G. Stavropoulos,et al.  2-Chlorotrityl chloride resin. Studies on anchoring of Fmoc-amino acids and peptide cleavage. , 2009, International journal of peptide and protein research.

[27]  B. Hudson,et al.  Intestinal basement membrane of Ascaris suum. Analysis of polypeptide components. , 1977, The Journal of biological chemistry.

[28]  Jeremy Green,et al.  NG-2,2,5,7,8-pentamethylchroman-6-sulphonyl-L-arginine: A new acid labile derivative for peptide synthesis , 1987 .